Cycle Pharmaceuticals announces the launch of PHYRAGO, its first oncology product in the US. PHYRAGO is launched in ...

When oral medicines for Chronic Myeloid Leukemia (CML) first became available, they dramatically changed what it meant to ...

Scemblix is the only CML treatment with a superior efficacy and favorable safety and tolerability profile versus available first-line treatments1,2 Despite available first-line treatments, 50% of ...

Scemblix showed a 68% major molecular response rate at 48 weeks, outperforming tyrosine kinase inhibitors by 19%. Common side effects included rash, musculoskeletal pain, and fatigue, with laboratory ...

Danziten, a new formulation of nilotinib, may improve treatment adherence in patients with Philadelphia chromosome-positive chronic myeloid leukemia. The Food and Drug Administration (FDA) approved ...

A CML diagnosis, often striking young Indian adults, is now more manageable. This guide emphasizes empowering patients by ...

The Food and Drug Administration (FDA) has sent out 12 more Untitled Letters to pharma companies amid its ongoing crackdown ...

December 12, 2006 (Orlando) — A new aurora kinase inhibitor is the first to show clinical activity in a population of treatment-resistant leukemia patients with a poor prognosis. The new Merck and ...

Granulocytic sarcomas are rare, destructive, extramedullary tumor masses that consist of immature granulocytic cells. The term "chloroma" is derived from the Greek word chloros (for green). It ...

The former Hollywood producer is receiving treatment in jail, sources said. Harvey Weinstein has been diagnosed with a form of bone marrow cancer, sources told ABC News. Weinstein has been diagnosed ...